
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication is sponsored by Janssen Pharmaceuticals, Inc.
The ongoing SUSTAIN-3 trial (NCT02782104) investigates the long-term safety and efficacy of individualized, intermittently dosed esketamine nasal spray used with an oral antidepressant in patients with treatment-resistant depression. This clinical brief reviews both the established short-term efficacy and safety profile of esketamine nasal spray and the study design and interim analysis results of the SUSTAIN-3 study.






